Ticker: JSPR

Jasper Therapeutics (NASDAQ: JSPR) shares plummeted 43.7% in premarket trading due to issues with a drug lot affecting its clinical study on briquilimab. The company is investigating the manufacturing problems, halting its ETESIAN asthma study, and implementing cost-cutting measures.